About Aclaris Therapeutics, Inc.Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Aclaris is based in Malvern, Pennsylvania. Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Aclaris Therapeutics, Inc., including statements about Aclaris's anticipated public offering, anticipated use of proceeds and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials and such other factors as are set forth in the risk factors detailed in Aclaris's Annual Report on Form 10-K for the year ended December 31, 2015, Aclaris's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 and Aclaris's other filings with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Aclaris's views as of the date hereof. Aclaris anticipates that subsequent events and developments will cause Aclaris's views to change. However, while Aclaris may elect to update these forward-looking statements at some point in the future, Aclaris specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Aclaris's views as of any date subsequent to the date hereof.
Contact: Aclaris Contact Michael Tung, M.D. Vice President / Investor Relations 484-329-2140 firstname.lastname@example.org Media Contact Mariann Caprino TogoRun 917-242-1087 M.Caprino@togorun.com